drugset
drugset / Trial / NCT07341100

Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC

NCT07341100 ↗

Phase 2 Active not recruiting 20 enrolled Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label study to evaluate the preliminary efficacy of SKB264 and the effect of clarithromycin on the PK of SKB264 in patients with ovarian epithelial cancer.

Timeline

Start
2026-01-16
Primary completion
2028-01
Completion
2028-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Clarithromycin Small molecule 500 mg Oral
Subject Sacituzumab Tirumotecan Other / unclassified 4 mg/kg Intravenous

Indications

malignant epithelial tumor of ovary